Aspira Women's Health Appoints New CMO, Director
Ticker: AWHL · Form: 8-K · Filed: Apr 26, 2024 · CIK: 926617
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
Aspira Women's Health brings in a new CMO and a new board member, potentially signaling a new direction.
AI Summary
Aspira Women's Health Inc. announced on April 22, 2024, the appointment of Dr. Michael W. McNeely as Chief Medical Officer and the election of Ms. Karen L. King to its Board of Directors. Dr. McNeely will also serve as a member of the company's management team. The company also disclosed compensatory arrangements for its officers.
Why It Matters
The appointment of a new Chief Medical Officer and a new Board member can signal strategic shifts or a renewed focus on medical innovation and governance for Aspira Women's Health.
Risk Assessment
Risk Level: medium — Changes in key leadership and board composition can indicate internal shifts that may impact the company's future strategy and performance.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- Dr. Michael W. McNeely (person) — Appointed Chief Medical Officer
- Ms. Karen L. King (person) — Elected to Board of Directors
- April 22, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer of Aspira Women's Health Inc.?
Dr. Michael W. McNeely has been appointed as the new Chief Medical Officer of Aspira Women's Health Inc.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 22, 2024.
Who was elected to the Board of Directors of Aspira Women's Health Inc.?
Ms. Karen L. King was elected to the Board of Directors of Aspira Women's Health Inc.
What other role will Dr. Michael W. McNeely hold?
Dr. Michael W. McNeely will also serve as a member of the company's management team.
What is the primary business of Aspira Women's Health Inc. according to the filing?
Aspira Women's Health Inc. is involved in IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Filing Stats: 402 words · 2 min read · ~1 pages · Grade level 12.8 · Accepted 2024-04-26 16:56:36
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Market
Filing Documents
- awh-20240422x8k.htm (8-K) — 64KB
- 0000926617-24-000031.txt ( ) — 184KB
- awh-20240422.xsd (EX-101.SCH) — 2KB
- awh-20240422_lab.xml (EX-101.LAB) — 15KB
- awh-20240422_pre.xml (EX-101.PRE) — 11KB
- awh-20240422x8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: April 26, 2024 By: /s/ Torsten Hombeck Torsten Hombeck Chief Financial Officer